Abstract
Background
Self-report measures are the most used methodologies for the evaluation of adherence to psoriasis topical treatment, although currently there is no standard questionnaire for this purpose.
Objective
The present study aimed at developing a novel questionnaire (Questionnaire for Adherence to TOPical treatment [QATOP]) for the assessment of adherence to topical treatment in psoriasis.
Methods
A questionnaire containing nine items organized into two parts (part 1: current patient treatment; part 2: adherence to treatment, amount used, and treatment-associated variables) was developed, supported by a systematic literature review, qualitative patient focus interviews, and expert-group input. Its content validity was determined by a pilot study of six patients. Adherence to topical treatment was then assessed in 35 patients with psoriasis, after 45 days of treatment, using the QATOP and a medication log. Associations between different items of the QATOP and the log were investigated.
Results
Adherence results were 63.5 ± 29.2% for the log and 60.9 ± 24.4% for the QATOP, and were strongly correlated (R = 0.819, p < 0.001). Distinct posologic regimens were reported by patients, which, in some cases, were not the usual doses. Patients also reported using doses of medicine on each application that were markedly lower than required.
Conclusion
The QATOP is a valid and reliable self-report measure of adherence to topical treatment in patients with psoriasis. The use of this standard questionnaire could improve the methodological quality of adherence studies. Improvement of the clarity of posologic instructions is clearly urgently needed.
Similar content being viewed by others
References
Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510–8.
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–42.
Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol. 2011;147(4):419–24.
Patel R, Shelling M, Prodanovich S, Federman D, Kirsner R. Psoriasis and vascular disease—risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011;26(9):1036–49.
Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47(4):512–8.
Almeida V, Taveira S, Teixeira M, Almeida I, Rocha J, Teixeira A. Emotion regulation in patients with psoriasis: correlates of disability, clinical dimensions, and psychopathology symptoms. Int J Behav Med. 2016. doi:10.1007/s12529-016-9617-0.
Branco M, Nogueira P, Conteiras T. Uma observação sobre a prevalência de algumas doenças crónicas em Portugal continental. In: Ministério da Saúde editor. Lisbon: Observatório Nacional de Saúde; 2005. p. 24.
Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16–7.
Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. J Am Acad Dermatol. 2011;65(4):870–3.
World Health Organization. Global report on psoriasis. Geneva: World Health Organization; 2016.
Al Raddadi AA, Fatani MI, Shaikh YH, Thaci D, Al Reshaid AA, Al-Eisa AM, et al. Adopted guidelines of care for the topical management of psoriasis from American and German guidelines. J Dermatol Dermatolog Surg. 2011;15(1):5–13.
Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatolog Treat. 2016. doi:10.1080/09546634.2016.1254331.
Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33.
Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.
Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE. Medical adherence to topical corticosteroid preparations prescribed for psoriasis: a systematic review. J Dermatolog Treat. 2017;28(1):32–9.
Tiedemann M. Psoriasis patients’ experiences concerning medical adherence to treatment with topical corticosteroids. Psoriasis Targets Ther. 2016;6:113–9.
Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–74.
Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:61–7.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
Halioua B. Adherence: definitions and measurement methods: characteristics of adherence to topical treatments. Ann Dermatol Venereol. 2012;139(1):S1–6.
Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28(12):1097–107.
Teixeira A, Teixeira M, Almeida V, Torres T, Sousa Lobo JM, Almeida IF. Methodologies for medication adherence evaluation: focus on psoriasis topical treatment. J Dermatol Sci. 2016;82(2):63–8.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241–7.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.
Duong M, Piroth L, Grappin M, Forte F, Peytavin G, Buisson M, et al. Evaluation of the patient medication adherence questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens. HIV Clin Trials. 2001;2(2):128–35.
Culig J, Leppee M. From Morisky to Hill-bone; self-reports scales for measuring adherence to medication. Coll Antropol. 2014;38(1):55–62.
Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K. Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). Arch Dermatol Res. 2014;306(3):287–97.
Teixeira A, Teixeira M, Rocha J, Sousa Lobo JM, Almeida IF, Almeida V. Development of instruments for the evaluation of adherence to topical treatment in psoriasis. Revista Portuguesa de Farmácia. 2011;LII(6):117–8.
Fleischer AB Jr, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol. 1994;102(6):967–9.
Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Exum ML, Clark AR, et al. The self-administered Psoriasis Area and Severity Index is valid and reliable. J Invest Dermatol. 1996;106(1):183–6.
Feldman SR, Clark AR, Venkat AP, Fleischerl AB Jr, Anderson RT, Rajagopalan R. The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol. 2005;152(2):382–3.
Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis[quest]: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933–43.
Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: Results of a pilot study. J Am Acad Dermatol. 2003;49(4):651–4.
Long CC, Finlay AY. The finger-tip unit: a new practical measure. Clin Exp Dermatol. 1991;16(6):444–7.
Drasgow F. Polychoric and polyserial correlations. In: David HA, Nagaraja HN, editors. Encyclopedia of statistical sciences. Wiley; 2004. ISBN: 978-0-470-86080-9.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59.
Storm A, Benfeldt E, Andersen SE, Serup J. A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol. 2008;59(6):975–80.
de Korte J, Van Onselen J, Kownacki S, Sprangers MAG, Bos JD. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol. 2005;19(1):35–41.
Bewley A, Burrage DM, Ersser SJ, Hansen M, Ward C. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol. 2014;28(6):763–70.
Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CEM. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581–3.
van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200(4):292–8.
van de Kerkhof PC, Franssen M, de La Brassine M, Kuipers M. Calcipotriol cream in the morning and ointment in the evening: a novel regimen to improve compliance. J Dermatolog Treat. 2001;12(2):75–9.
Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19:2–6.
Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–13.
Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64–9.
Kivelevitch DN, Tahhan PV, Bourren P, Kogan NN, Gusis SE, Rodríguez EA. Self-medication and adherence to treatment in psoriasis. Int J Dermatol. 2012;51(4):416–9.
Saeki H, Imafuku S, Abe M, Shintani Y, Onozuka D, Hagihara A, et al. Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients. J Dermatol. 2015;42(4):367–72.
Acknowledgements
The authors would like to thank all patients who participated in this study, the Portuguese Association of Psoriasis (PSOPortugal) for assistance with data collection, and CESPU—Cooperativa de Ensino Superior Politécnico e Universitário for financial support of this study (projects 04-GCQF-CICS-2011N and POSOL-DERM-CESPU-2016). A. Rita Gaio was partially supported by CMUP—Centro de Matemática da Universidade do Porto (UID/MAT/00144/2013), which is funded by FCT—Fundação para a Ciência e a Tecnologia (Portugal) with national (MEC—Ministério da Educação e Ciência) and European structural funds through the FEDER—Fundo Europeu de Desenvolvimento Regional program, under partnership Agreement PT2020.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Ana Teixeira, Carolina Oliveira, Maribel Teixeira, A. Rita Gaio, José Manuel Sousa Lobo, Isabel Filipa Almeida and Vera Almeida have no conflicts of interest to declare.
Rights and permissions
About this article
Cite this article
Teixeira, A., Oliveira, C., Teixeira, M. et al. Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP). Am J Clin Dermatol 18, 571–581 (2017). https://doi.org/10.1007/s40257-017-0272-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-017-0272-2